πŸ‡ΊπŸ‡Έ FDA
Patent

US 10941210

Anti-PCSK9 antibodies

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10941210 (Anti-PCSK9 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/08, A61P